Trevi Therapeutics, Inc. Announces Management Changes
April 02, 2021 at 04:16 pm
Share
On March 29, 2021, Frank P. Muscolo, the controller and principal accounting officer of Trevi Therapeutics, Inc., and the company agreed that, in connection with the hiring of Christopher Galletta to serve as the company’s controller, Mr. Muscolo would cease to serve as the company’s principal accounting officer, effective upon April 12, 2021, Mr. Galletta’s start date with the company. Mr. Galletta was hired in anticipation of Mr. Muscolo’s planned retirement in early 2022. Mr. Muscolo will continue as an employee of the company until his retirement date. Upon his start date of April 12, 2021, Mr. Galletta will serve as the Company’s principal accounting officer. Mr. Galletta, 43, served as Director of Financial Reporting at SS&C Technologies Holdings, Inc., a publicly-traded global financial services and software company, from July 2016 until March 2021, and as Assistant Vice President, Corporate Accounting at Virtus Investment Partners, Inc., a publicly-traded investment management company, from October 2011 to July 2016.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
TREVI THERAPEUTICS, INC. 
